irritable bowel syndrome
Conditions
Interventions
Traditional Chinese medicine group:take NO.1 Granules
placebo group:take placebo
Health control:nothing
Sponsors
The First Affiliated Hospital of Guangzhou University of Chinese Medicine;International Institute of Translation Chinese Medicine,Guangzhou University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
20 Years to 50 Years
Inclusion criteria
Inclusion criteria: To simultaneously satisfy the following criteria: (1) Conform to the Roman IV(Rome IV) of a patient diagnosed with IBS-D; (2) Aged 20 to 50 years, gender not limited, born in south of the Five Ridges; (3) Nearly 1 weeks no using the drug in the treatment of IBS; (4) Nearly 2 weeks no using antibiotics or probiotics; (5) Be voluntary to drug treatment, and signed informed consent, the informed consent process in conformity with the relevant provisions of the GCP.
Exclusion criteria
Exclusion criteria: Meet one of the following criteria were excluded: 1. there is explanation above the clinical symptoms of the patients with other diseases; 2. chronic esophagitis, Barrett esophagus and gastroesophageal reflux disease, peptic ulcer, gastric polyp (without resection), digestive tract tumor patients; 3. found that endoscopic gastric mucosa high grade intraepithelial neoplasia, pathological diagnosis, malignant gastrointestinal organic diseases; 4. patients with history of abdominal operation; 5. allergic or allergic to many medicines; 6. confusion, dementia, psychosis, neurosis and various serious unwilling to cooperate; 7. with serious the primary cardiovascular disease, liver disease, kidney disease, blood disease, lung disease, autoimmune diseases, or serious diseases affected the survival, such as cancer or aids; 8. pregnant and lactating women; 9. exist cognitive or other damage (such as vision, etc.) and impact on the participants completed self-report; 10. of the pharmaceutical composition ingredients allergies are; is or 4 weeks in other drug clinical trials of patients; 11. investigators have sufficient reason to believe that the participants according to current medical or psychological state is not suitable for researchers to study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| intestinal flora; | — |
Secondary
| Measure | Time frame |
|---|---|
| IBS-SSS;IBS-QOL;HAD;CRO;SSDPRO-IBS;5-hydroxytryptamine; | — |
Countries
China
Contacts
Public ContactLIU Feng-bin
The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Outcome results
None listed